Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study

Dioun, S., Chen, L., Melamed, A., Gockley, A., St. Clair, C. M., Hou, J. Y., Khoury‐Collado, F., Hur, C., Elkin, E., Accordino, M., Hershman, D. L., & Wright, J. D. (2022). Dostarlimab for recurrent mismatch repair‐deficient endometrial cancer: A cost‐effectiveness study. BJOG: An International Journal of Obstetrics & Gynaecology, 130(2), 214–221. Portico. https://doi.org/10.1111/1471-0528.17338
Authors:
Shayan Dioun
Ling Chen
Alexander Melamed
Allison Gockley
Caryn M St Clair
June Y Hou
Fady Khoury-Collado
Chin Hur
Elena Elkin
Melissa Accordino
Dawn L Hershman
Jason D Wright
Affiliated Authors:
Shayan Dioun
Ling Chen
Alexander Melamed
Allison Gockley
Caryn M St Clair
June Y Hou
Fady Khoury-Collado
Chin Hur
Elena Elkin
Melissa Accordino
Dawn L Hershman
Jason D Wright
Columbia Affiliation:
Subjects:
DNA Mismatch Repair (MeSH)
Endometrial Neoplasms (MeSH)
Author Keywords:
cost-effectiveness
dostarlimab
pembrolizumab
recurrent endometrial cancer
recurrent uterine cancer
elink
Publication Type:
Article
Unique ID:
10.1111/1471-0528.17338
PMID:
36330672
DOI:
10.1111/1471-0528.17338
Journal:
BJOG
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: